EP300 and idiopathic pulmonary fibrosis: Additionally, the combination of EP300 inhibitor SGC-CBP300 and DDR1 inhibitor CQ-061 attenuated fibrotic (e.g., FN1 and COL1A1) and inflammatory (e.g., IL-4 and IFN-γ) effects in bleomycin-induced IPF murine models [66].